Literature DB >> 6162378

Circulating Charcot-Leyden crystals in the hypereosinophilic syndrome.

H P Dincsoy, T J Burton, J M van der Bel-Kahn.   

Abstract

A patient who had malignant melanoma associated with the hypereosinophilic syndrome died of cardiovascular thrombotic lesions. Widespread tissue eosinophilia was accompanied by numerous Charcot-Leyden crystals in the tumor as well as in various organs, including the renal tubules. A unique observation, not previously described, is the finding of Charcot-Leyden crystals in the thrombi and vessels, including the renal glomeruli. While little is known of the significance of Charcot-Leyden crystals, it is speculated that the circulating crystals injure the endothelium and trigger intravascular coagulation, resulting in thrombosis. A search for the crystals in blood and/or urine may be of additional aid in the evaluation of the extent of the thrombotic process. A special staining method is proposed to facilitate recognition of the crystals, since these are virtually not visualized by routine stain. With the use of such a staining method, future observations in other cases of the hypereosinophilic syndrome may elucidate the role of Charcot-Leyden crystals in the pathogenesis of the thrombotic cardiovascular lesions of this syndrome.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6162378     DOI: 10.1093/ajcp/75.2.236

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  3 in total

Review 1.  Primary malignant melanoma of the gall bladder.

Authors:  D I Heath; C Womack
Journal:  J Clin Pathol       Date:  1988-10       Impact factor: 3.411

Review 2.  Molecular epigenetic dynamics in breast carcinogenesis.

Authors:  Aadrita Hazra; Pritha Bose; Priyashree Sunita; Shakti P Pattanayak
Journal:  Arch Pharm Res       Date:  2021-08-15       Impact factor: 4.946

Review 3.  A Brief History of Charcot-Leyden Crystal Protein/Galectin-10 Research.

Authors:  Jiyong Su
Journal:  Molecules       Date:  2018-11-09       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.